Changes in DNA methylation in neoplasia: Pathophysiology and therapeutic implications

Annals of Internal Medicine

Volumn 134, Issue 7, 2001, Pages 573-586

  Santini, V ^a   Kantarjian, H M ^a   Issa, J P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 METHYLCYTOSINE; 5,6 DIHYDROAZACITIDINE; AMSACRINE; AZACITIDINE; CALCITONIN; DAUNORUBICIN; DNA; DNA METHYLTRANSFERASE; ETOPOSIDE; FAZARABINE; HEMOGLOBIN F; HISTONE; MITOXANTRONE; MYOD PROTEIN; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CELL TRANSFORMATION; CLINICAL TRIAL; CPG ISLAND; DIARRHEA; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG TARGETING; GENE SILENCING; HUMAN; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 0035799382     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-7-200104030-00011     Document Type: Review

References (112)

1. Alterations in DNA methylation: A fundamental aspect of neoplasia
2. Cancer epigenetics comes of age
3. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
4. A chronicle of DNA methylation (1948-1975)
5. DNA methylation in early development
6. DNA methyltransferases
7. Genetic and epigenetic aspects of DNA methylation on genome expression, evolution, mutation and carcinogenesis
8. DNA methylation and gene function
9. Methylation of DNA in prokaryotes
10. Nonmethylated transposable elements and methylated genes in a chordate genome
11. Creation of genomic methylation patterns
12. Gametic imprinting in mammals
13. Regulation of X-chromosome inactivation in development in mice and humans
14. CpG-rich islands and the function of DNA methylation
15. Altering gene expression with 5-azacytidine
16. Role for DNA methylation in genomic imprinting
17. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription
18. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
19. Hypomethylation of ras oncogenes in primary human cancers
20. DNA hypomethylation leads to elevated mutation rates
21. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas
22. De novo methylation of the MyoD1 CpG island during the establishment of immortal cell lines
23. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene
24. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma
25. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers
26. The E-cadherin gene is silenced by CpG methylation in human hepatocellular carcinomas
27. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines
28. Roles of cell division and gene transcription in the methylation of CpG islands
29. Aging and DNA methylation in colorectal mucosa and cancer
30. CpG island methylator phenotypes in aging and cancer
31. Cell cycle-dependent regulation of eukaryotic DNA methylase level
32. Aging, DNA methylation and cancer
33. CpG island methylator phenotype in colorectal cancer
34. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies
35. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation
36. Altered methylation of the human MDR1 promoter is associated with acquired multidrug resistance
37. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms
38. HIC1 hypermethylation is a late event in hematopoietic neoplasms
39. DNA methylation as a target for drug design
40. Pharmacokinetics of 5-aza-2′-deoxycytidine in animals and man: Relevance to clinical trials
41. Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines
42. 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model
43. Suppression of intestinal neoplasia by DNA hypomethylation
44. 5-Aza-2′-deoxycytidine: An overview
45. Inhibition of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine
46. Biochemical pharmacology of 5,6-dihydro-5-aza-cytidine (DHAC) and DNA hypomethylation in tumor (L1210)-bearing mice
47. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor
48. Cellular differentiation, cytidine analogs and DNA methylation
49. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation
50. Effects of dose and duration of exposure on 5-aza-2′-deoxycytidine cytotoxicity for L1210 leukemia in vitro
51. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine
52. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias
53. InhibitIon of DNA methyltransferase and induction of friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine
54. Effects of 5-aza-2′ deoxycytidine on erythroid differentiation and globin synthesis of the human leukemic cell line K 562
55. Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937
56. Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine
57. 5-Aza-2′-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly
58. Induction of differentiation and inhibition of DNA methylation in HL-60 myeloid leukemic cells by 5-AZA-2′-deoxycytidine
59. Comparison of the in vitro cytotoxicity (L1210) of 5-aza-21-deoxycytidine with its therapeutic and toxic effects in mice
60. Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia
61. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia
62. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia
63. Phase II study of 5-azacytidine (NSC-102816) in the treatment of advanced gastrointestinal cancer
64. Phase I study of 5-azacytidine (NSC-102816)
65. Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271)
66. Clinical trial with subcutaneously administered 5-azacytidine (NSC-102816)
67. Phase II study of 5-azacytidine in solid tumors
68. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas
69. Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma
70. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer
71. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer
72. Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer
73. A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880)
74. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: A phase II study by the Cancer and Leukemia Group B
75. A phase II study of 5,6-dihydro-5-azacytidine hydrochloride in disseminated malignant melanoma
76. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity
77. Treatment of acute leukemia with 5-azacytidine (NSC-102816)
78. 5-Azacytidine: A new active agent for the treatment of acute leukemia
79. 5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia
80. 5-Azacytidine (NSC 102816): A new drug for the treatment of myeloblastic leukemia
81. Effect of schedule on activity and toxicity of 5-azacytidine in acute leukemia: A Southwest Oncology Group Study
82. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: A phase I-II trial of the Southeastern Cancer Study Group
83. Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study
84. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: A Pediatric Oncology Group randomized phase II study
85. Phase I study on 5-aza-2′-deoxycytidine in children with acute leukemia
86. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia
87. A randomized phase II study on the effects of 5-aza-2′-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: An EORTC Leukemia Cooperative Group phase II study (06893)
88. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia
89. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukemia
90. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: Preliminary results
91. Decitabine (5-Aza-2′-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary observations
92. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial)
93. Dose intensification in acute myeloid leukaemia: Greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party
94. Alternating v repeated postremission treatment in adult acute myelogenous leukemia: A randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group
95. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes
96. 5-azacytidine in myelodysplastic syndromes (MDS): The experience at Mount Sinai Hospital, New York
97. A randomized controlled trial of subcutaneous azacytidine (AZA C) in patients with myelodysplastic syndromes (MDS): A study of the cancer and leukemia group B, American Society of Clinical Oncology 34th Meeting, Los Angeles
98. The impact of 5-azacytidine on the quality of life of patients with myelodysplastic syndrome (MDS) treated in a randomized phase III trial of the Cancer and Leukemia Group B
99. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome
100. Low-dose 5-aza-2′deoxycytidine, a DNA hypomethylating agent, for the treatment of hish-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
101. DNA demethylating therapy in MDS - The experience with 5-aza-2′-deoxycytidine (decitabine)
102. Reduction of p15 hypermethylation in bone marrow cells from patients with MDS following treatment with a methyltransferase inhibitor, decitabine
103. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213
104. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the Eastern Cooperative Oncology Group
105. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia
106. Chronic myelogenous leukemia in nonlymphoid blastic phase: Analysis of the results of first salvage therapy with three different treatment approaches for 162 patients
107. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer
108. Activation of the retinoic acid receptor beta gene by 5-aza-2′-deoxycytidine in human DLD-1 colon carcinoma cells
109. Enhanced sensitivity to topoisomerase inhibitors in synchronous CHO cells pre-treated with 5-azacytidine
110. Effects of 5-aza-2′-deoxycytidine and interferon-alpha on differentiation and oncogene expression in HL-60 myeloid leukemic cells
111. Expression of antisense to DNA methyltransferase mRNA induces DNA demethylation and inhibits tumorigenesis
112. Crystal structure of the HhaI DNA methyltransferase complexed with S-adenosyl-L-methionine